论文信息 - Tuberculosis due to Mycobacterium bovis after alemtuzumab administration. - 字舞流文

Tuberculosis due to Mycobacterium bovis after alemtuzumab administration.

We describe a patient with relapsing B chronic lymphocytic leukemia who developed systemic bacille Calmette-Guérin infection (BCGitis) after administration of alemtuzumab (Campath-1H).

D. Bouscary | D. Sicard | F. Dreyfus | L. Moachon | P. Blanche | S. Abad | E. Gyan

[1] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[2] M. Dyer,et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] M. Urowitz,et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. , 1995, Arthritis and rheumatism.

[4] L. Weiss,et al. Severe anemia as the presenting manifestation of giant cell arteritis. , 1995, Arthritis and rheumatism.

[5] J. Falkenburg,et al. In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. , 1992, Bone marrow transplantation.